Alle Storys
Folgen
Keine Story von IsoTis OrthoBiologics mehr verpassen.

IsoTis OrthoBiologics

IsoTis Receives US Patent Related to Reverse Phase Medium Technology

Irvine, California (ots/PRNewswire)

IsoTis, Inc. (NASDAQ: ISOT),
the orthobiologics company, today announced that the United States
Patent and Trademark Office has awarded US Patent No. 7,205,337,
which relates to the company's Reverse Phase Medium (RPM) carrier
technology.
The patent covers the use of IsoTis' current RPM technology in
combination with various demineralized bone matrix (DBM)
formulations, such as those based on the company's innovative Accell
technology. IsoTis has also received a notice of allowance for a
patent application covering the use of the entire RPM formulation in
combination with a complete range of synthetic and natural bone graft
substitute compounds.
The favorable handling characteristics of a number of IsoTis'
products, such as Accell Connexus, are to a large extent attributable
to the RPM technology. RPM technology enables the product to flow at
operating room temperature but thicken to a gel when placed in the
body and warmed to body temperature. Orthopedic surgery is often open
surgery, requiring regular irrigation and suction at the surgical
site to clear the operating field. RPM enables the surgeon to shape
and form the product outside the body to fit the surgical site, and
once the product is placed within the body, it thickens and can
resist displacement by irrigation. By resisting displacement, more of
the components with osteoinductive potential of the product are held
in place at the graft site, where they can effect bone formation.
Pieter Wolters, President and CEO of IsoTis said, "The RPM
technology is an essential part of a number of our products. We
believe that RPM contributes to the favorable handling
characteristics of our products, which differentiate us from other
products in the market. Following the key patent awarded last year
for our Accell platform technology, we believe this patent and the
notice of allowance further secure intellectual property protection
for our 2nd platform technology. "
About IsoTis, Inc.
IsoTis is a leading orthobiologics company that develops,
manufactures and markets proprietary products for the treatment of
musculoskeletal diseases and disorders. IsoTis' current
orthobiologics products are bone graft substitutes that promote the
regeneration of bone and are used to repair natural, trauma-related
and surgically-created defects common in orthopedic procedures,
including spinal fusions. IsoTis' current commercial business is
highlighted by its Accell line of products, which the company
believes represents the next generation in bone graft substitution.
Certain statements in this press release are "forward-looking
statements" within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, including those that refer to
management's plans and expectations for future operations, prospects
and financial condition. Words such as "strategy," "expects,"
"plans," "anticipates," "believes," "will," "continues," "estimates,"
"intends," "projects," "goals," "targets" and other words of similar
meaning are intended to identify such forward-looking statements. One
can also identify them by the fact that they do not relate strictly
to historical or current facts. Such statements are based on the
current expectations of the management of IsoTis only. Undue reliance
should not be placed on these statements because, by their nature,
they are subject to known and unknown risks and can be affected by
factors that are beyond the control of IsoTis. Actual results could
differ materially from current expectations due to a number of
factors and uncertainties affecting IsoTis' business, including, but
not limited to, a competitive sales and marketing environment, the
timely commencement and success of IsoTis' clinical trials and
research endeavors, delays in receiving U.S. Food and Drug
Administration or other regulatory approvals (a.o. EMEA, CE),
including the risk that the FDA determines that our Accell Putty and
Accell TBM products are not human tissue or class II medical devices,
that the Company is unable to obtain 510(k) clearance for its Accell
products, that the FDA requires the Company to obtain premarket
approval of its Accell products prior to continuing their marketing,
that the FDA requires the Company to produce additional clinical data
to support approval or clearance of its products, that the FDA
imposes compliance measures against the Company for the marketing of
its Accell products, including imposing fines and injunctions or
causing the Company to recall its Accell products, market acceptance
of IsoTis' products, effectiveness of IsoTis' distribution channels,
development of competing therapies and/or technologies, the terms of
any future strategic alliances, the need for additional capital, the
inability to obtain, or meet, conditions imposed for required
governmental and regulatory approvals and consents. IsoTis expressly
disclaims any intent or obligation to update these forward-looking
statements except as required by law. For a more detailed description
of the risk factors and uncertainties affecting IsoTis, refer to the
Annual Report on Form 20-F for the fiscal year ended December 31,
2005 of IsoTis SA, the predecessor of the Company, filed with the
SEC, to IsoTis SA's reports filed from time to time with the Swiss
Stock Exchange (SWX), Euronext Amsterdam N.V., SEDAR at www.sedar.com
and the Toronto Stock Exchange (TSX), and to the reports filed from
time to time by the Company with the SEC.

Contact:

For information contact: Rob Morocco, CFO,+1-949-855-7155,
robert.morocco@isotis.com; Hans Herklots, Director IR,
+1-949-855-7195 or +41-21-620-6011, hans.herklots@isotis.com

Weitere Storys: IsoTis OrthoBiologics
Weitere Storys: IsoTis OrthoBiologics
  • 25.04.2007 – 14:17

    IsoTis Completes Transfer of PolyActive IP Estate to OctoPlus

    Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced it has completed the transfer of the rights associated with its PolyActive technology to OctoPlus (Euronext: OCTO), a drug delivery and development company, in exchange for an up-front payment of approximately $1.7 million and future royalty payments on sales of pharmaceutical products based on the ...

  • 16.04.2007 – 14:15

    /C O R R E C T I O N -- Isotis Inc/

    Irvine, California (ots/PRNewswire) - In the news release, "IsoTis Appoints James P. Abraham as Senior Vice President Sales" issued on 16 Apr 2007 12:00 GMT, by Isotis Inc nasdaq:ISOT over PR Newswire, we are advised by a representative of the company that the release is the same for several wire tasks, so the destinations will be added to this task transmitted by PR Newswire. Complete, corrected release follows: ...

  • 14.02.2007 – 15:14

    IsoTis Reports Preliminary 2006 and Q4 Revenue

    Irvine, California (ots/PRNewswire) - - Update on Recent Events IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today reported preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2006. Revenue was approximately US$10 million (unaudited) for the fourth quarter of 2006, representing a 16% increase over revenue of the fourth quarter of 2005. For the full year 2006, ...